Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo ...

Veteran oncology executive brings global development and regulatory expertise to support TCB's life sciences strategy HOUSTON, TX, UNITED STAT ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

Halozyme (HALO) says the European Commission OK'd an injectable version of J&J's (JNJ) cancer drug, Rybrevant for certain ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved an extension of marketing ...

ServiceChannel, the leading platform for the procurement and delivery of facilities services, has introduced a new online ecosystem that offers multi-site customers and service providers access to a ...

World Health Day, the Personal Care Products Council (PCPC) launched the #WearSunscreen campaign, a nationwide effort urging the public to protect their skin with sunscreen use every day. Slightly ...

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.